Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial

by Rella Zoleko-Manego, Ruth Kreuzmair, Luzia Veletzky, Wilfrid Ndzebe-Ndoumba, Dorothea Ekoka Mbassi, Dearie G. Okwu, Lia B. Dimessa-Mbadinga-Weyat, Roselyne D. Houtsa-Temgoua, Johannes Mischlinger, Matthew B. B. McCall, Peter G. Kresmner, Selidji T. Agnandji, Betrand Lell, Ayôla A. Adegnika, Ghyslain Mombo-Ngoma, Michael Ramharter

Background

There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon.

Methods

Eligible adult patients with L. loa microfilaraemia between 5,000 and 50,000 microfilariae/ml were randomized to either a control or one of three intervention groups (1:2:2:2 allocation ratio) consisting of three-week twice daily 400mg oral albendazole followed by 1) no treatment, 2) two further weeks of twice daily 400mg albendazole, or 3) a single dose of ivermectin in this open label randomized assessor blinded controlled clinical trial. The primary outcome was the proportion of participants with L. loa microfilaraemia ≤ 100 mf/ml at Day 168.

Results

In the efficacy-population of 42 patients 0 (0%; control group), 1 (9%; 3-week albendazole), 5 (39%; 5-weeks albendazole) and 2 (22%; 3-week albendazole plus single dose ivermectin) participants met the primary outcome of microfilaraemia below 100/ml at day 168. A 80–90% reduction of microfilaraemia was observed in the active treatment groups.

Conclusion

The 5-week regimen of albendazole or a 3-week regimen of albendazole followed by ivermectin were most efficacious to reduce microfilaraemia. All therapeutic regimens were well tolerated and safe.

Trial registration

Trial registered at the Pan-African Clinical Trials Registry: PACTR201807197019027.